Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 December 2021 Photo Supplied
Besides being the top medical student at UFS in 2021, Dr Mario Vieira is passionate about food, music and sport, and plays the piano and guitar for leisure.

Dr Mario Vieira, one of the University of the Free State’s (UFS) newest graduates in the MBChB programme, says he is fortunate and blessed to graduate from the Faculty of Health Sciences as the top achiever in the class of 2021. Dr Vieira will graduate at the year-end ceremonies. 

Says Dr Vieira: “Privileged is the first word that comes to mind. Yet, there are so many other emotions and feelings involved. One is relieved that the hard work is over for now, but in the same breath, quite sad that this chapter of one’s life has come to an end. Excitement also comes through, knowing that a new challenge lies ahead.” 

Dr Vieira says being the top achiever is undeniably an unbelievable achievement, but there were many other factors and people who made it possible. His family, especially his parents, were his greatest motivation. Their unconditional love and support have made his success possible. 

Multiple factors led to medicine 

According to Dr Vieira, who wanted to be a pilot when he was growing up, there were multiple factors that led to him eventually study medicine. He says: “My first experience with medicine was at a young age when I lost a good friend of mine to cancer. I believe the seed that was planted began to grow when my brother started studying medicine. 
“In high school I made the decision once I realised I was passionate about people and would love to make a difference in the life of others. I think it was the idea that if one could pass this degree, one would be equipped and capable to change lives on a daily basis. My friends in medicine and the support system in Bloemfontein were also incredibly valuable. When times were tough, we would carry each other through,” says Dr Vieira on graduating in one of the university’s toughest fields.

He is starting his internship on 1 January 2022 at Addington Hospital in Durban. 

Besides medicine, this Bothaville, Free State native is also passionate about food, music and sport. He loves cooking and hopes to retire one day with a small restaurant by the sea – cooking food and putting smiles on people’s faces. He also loves playing piano and the guitar.

His message to other students who might be considering studying medicine is: “Be courageous. You are capable of more than you think. Believe in yourself. Hard work, determination and time management can get you where you want to be.” 

Your courage 

Prof Lynette van der Merwe, who took up her new position as Academic Head in the Division Health Sciences Education, Faculty of Health Sciences on 1 December 2021, congratulated the new cohort of UFS doctors and reminded them of the three Cs in the MBChB programme in 2021 – courage, conviction and compassion.

 “I saw your courage, the way you squared your shoulders and looked personal, academic and financial problems in the eye, and endured. You were brave and strong when it mattered most. and stayed true to yourself despite overwhelming odds. You made good choices although they were hard, you found a way to put one foot in front of the other when you were too tired to even think.”

“In the words of the poet Amanda Gorman, “There is always light, if only we’re brave enough to see it. If only we’re brave enough to be it. May you always carry your light into a dark world.” 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept